ArticleJournal of inflammation (London, England)2026
Electroacupuncture activates the TET1/PPARα pathway to protect mitochondrial function in MASLD.
Article in Journal of inflammation (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMetabolic associated steatotic liver disease (MASLD), characterized by mitochondrial dysfunction. It may be ameliorated by electroacupuncture (EA) through activation of the ten-eleven translocation 1 (TET1)/peroxisome proliferator-activated receptor-α (PPARα) pathway, thereby restoring mitochondrial function.
methodsC57BL/6 mice were fed L-amino acid rodent diet with 60 kcal% fat, low methionine and no added choline (CDAHFD) and high fat diet (HFD) for three weeks to induce MASLD, followed by EA treatment and daily intraperitoneal injections of a TET1 agonist or antagonist. Hepatic lipid accumulation, inflammatory cytokines, reactive oxygen species (ROS), and mitochondrial function were evaluated by biochemical assays, enzyme-linked immunosorbent assay (ELISA), flow cytometry, and transmission electron microscopy (TEM), western blotting (WB) and reverse transcription quantitative polymerase chain reaction (RT-qPCR).
resultsEA reduced hepatic total cholesterol (TC), triglycerides (TG), and free fatty acids (FFA), and decreased the size of lipid droplets. It restored mitochondrial membrane potential, ATP production, and cristae integrity, while attenuating ROS accumulation and suppressing pro-inflammatory cytokine levels. Moreover, EA upregulated TET1 expression, enhanced genomic 5-hydroxymethylcytosine (5-hmC) enrichment, and elevated PPARα expression. These effects were comparable to those of a TET1 agonist, whereas administration of a TET1 antagonist partially reversed them.
conclusionEA ameliorates MASLD by activating the TET1/PPARα pathway, thereby enhancing mitochondrial function and reducing oxidative stress and inflammation. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.